Tirzepatide vs Retatrutide: the honest comparison
Retatrutide is the more aggressive compound — Phase II data showed ~24% weight loss at 48 weeks on the top dose vs Tirzepatide's ~22% at 72 weeks. But Tirzepatide is FDA approved with years of real-world data; Retatrutide is still in trials. For most people, Tirzepatide is the right choice until Retatrutide completes Phase III.
Side-by-side facts
| Tirzepatide | Retatrutide | |
|---|---|---|
| Class | Dual GIP / GLP-1 receptor agonist | Triple GIP / GLP-1 / glucagon receptor agonist |
| Half-life | Approximately 5 days (once-weekly dosing) | Approximately 6 days (once-weekly dosing) |
| Typical dose | Titration: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly | Titration: 2 mg → 4 mg → 8 mg → 12 mg weekly (trial protocols) |
| Category | GLP-1/GIP / metabolic | GLP-1/GIP/glucagon / metabolic |
| FDA status | FDA approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). Compounded tirzepatide currently faces the same FDA scrutiny as semaglutide. | Investigational. Eli Lilly Phase 3 trials ongoing as of 2026. Not FDA approved. |
| Storage | Lyophilized refrigerated preferred. | Lyophilized refrigerated. |
What they have in common
Both are once-weekly injectable agonists at the GLP-1 and GIP receptors, both produce large fat-loss effects, and both are in the same structural family. Retatrutide extends the mechanism by adding glucagon-receptor agonism on top.
When to pick Tirzepatide
Pick Tirzepatide when you want a clinically proven, FDA-approved compound with a known long-term safety profile. It is the right default for 2026 — the trial data is mature, supply is stable, and most endocrinologists prescribe it routinely.
When to pick Retatrutide
Pick Retatrutide when you need faster or deeper fat loss than Tirzepatide delivers at the top dose, accept the research-use-only regulatory status, and can access a reliable source. The glucagon-receptor arm adds energy expenditure, which is part of why weight loss runs deeper — but it also makes titration more nausea-prone.
Can you stack them?
No — stacking two incretin agonists multiplies GI side effects with no proven benefit. Step up from one to the other if fat loss plateaus.
The two compounds
Tirzepatide
Tirzepatide is a synthetic dual incretin agonist activating both GIP and GLP-1 receptors. Clinical trials show weight loss and glycemic e…
Retatrutide
Retatrutide is an investigational triple agonist at GIP, GLP-1, and glucagon receptors. Phase 2 trial data reported weight loss exceeding…
Track either compound on iPhone
Peptide Protocol schedules doses, calculates reconstitution, and logs side effects for both — on iPhone, free to download.
See the app →Frequently asked questions
What is the main difference between Tirzepatide and Retatrutide?
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon); Tirzepatide is a dual agonist (GLP-1 + GIP). The glucagon-receptor addition is what unlocks the extra energy-expenditure effect driving Retatrutide's deeper weight loss.
Can you stack Tirzepatide and Retatrutide?
No — stacking two incretin agonists multiplies GI side effects with no proven benefit. Step up from one to the other if fat loss plateaus.
Which is better, Tirzepatide or Retatrutide?
Retatrutide is the more aggressive compound — Phase II data showed ~24% weight loss at 48 weeks on the top dose vs Tirzepatide's ~22% at 72 weeks. But Tirzepatide is FDA approved with years of real-world data; Retatrutide is still in trials. For most people, Tirzepatide is the right choice until Retatrutide completes Phase III.
When should I pick Tirzepatide?
Pick Tirzepatide when you want a clinically proven, FDA-approved compound with a known long-term safety profile. It is the right default for 2026 — the trial data is mature, supply is stable, and most endocrinologists prescribe it routinely.
When should I pick Retatrutide?
Pick Retatrutide when you need faster or deeper fat loss than Tirzepatide delivers at the top dose, accept the research-use-only regulatory status, and can access a reliable source. The glucagon-receptor arm adds energy expenditure, which is part of why weight loss runs deeper — but it also makes titration more nausea-prone.
Are Tirzepatide and Retatrutide FDA approved?
Tirzepatide: FDA approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). Compounded tirzepatide currently faces the same FDA scrutiny as semaglutide. — Retatrutide: Investigational. Eli Lilly Phase 3 trials ongoing as of 2026. Not FDA approved.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.